GHRHR antagonists may target certain complications of diabetes, especially in Type 1 diabetes and insulin-dependent T2DM, where insulin production by the beta-cell is at least clinically insignificant. The gene discussed is GHRHR; the disease is type 2 diabetes mellitus.